Novartis
European Society for Medical Oncology Congress 2021: Precision Oncology Data Roundup
Researchers presented data at the meeting on biomarker-directed therapies and tests to characterize patients' responses to cancer treatment.Â
Novartis' Kymriah Fails to Meet Primary Endpoint in Phase III NHL Trial
The autologous CAR T-cell therapy did not improve event-free survival versus standard-of-care chemo aggressive B-cell non-Hodgkin lymphoma patients.
Turning Point Therapeutics Begins Study of Repotrectinib, Mekinist in KRAS G12D-Mutated Cancers
The TRIDENT-2 trial will evaluate Turning Point's investigational agent plus Novartis' MEK inhibitor in advanced solid tumors harboring KRAS G12D mutations.
Novartis Q2 Revenues Grow 14 Percent
The firm saw growth across key precision oncology assets including targeted and cell therapies, despite lower patient volumes relative to pre-pandemic levels.
FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC
The blood-based test is the second Foundation Medicine assay approved to ID patients eligible for the drug due to mutations leading to MET exon 14 skipping.